EGFR and leukemia: Similarly, lestaurtinib, another staurosporine derivative, has mainly been studied in leukemia where it has demonstrated good tolerability with mean trough concentrations of ∼3.75 mM achievable with twice daily dosing that again exceeds the concentration necessary for EGFR phosphorylation inhibition in cells (Marshall et al, 2005).